<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>418-PIOGLITAZONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PIOGLITAZONE" rxcui="33738">
<ATC code="A10BG03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SOMATOSTATIN ANALOGS" code="H01CB0-001" /></DRUG2>
<DESCRIPTION>Risk of hyypoglycemia or hyperglycemia: decrease or increase of the need for glitazone, due to decrease of increase of the secretion of endogenous glucagon</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increase self monitoring of blood glucose and adjust if needed the dosage of the glitazone during the treatment with the somatostatin analog</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>418-PIOGLITAZONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PIOGLITAZONE" rxcui="33738">
<ATC code="A10BG03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GEMFIBROZIL" rxcui="4719">
<ATC code="C10AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the glitazone due to decrease of its hepatic metabolism by the gemfibrozil</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these medications together cannot be avoided, strict clinical monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>418-PIOGLITAZONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PIOGLITAZONE" rxcui="33738">
<ATC code="A10BG03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the glitazone due to increase of its metabolism by the rifampcin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring; adjustment of the dosage of the glitazone during the treatment with the rifampicin and after it is stopped. </COMMENT>
</INTERACTION>
</INTERACTIONS>
